BofA lowered the firm’s price target on Royalty Pharma to $38 from $40 and keeps a Buy rating on the shares. The firm notes its estimates are largely in-line with the Street for Q1 and 2024, but cites changes in net cash for its lowered target in a Large Cap Biotech and Pharma earnings preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>